MaxCyte (MXCT) has released an update.
MaxCyte, Inc. has entered into a strategic license agreement with Kamau Therapeutics to use its Flow Electroporation® technology and ExPERT™ platform, aiming to advance the development of cell therapies for genetic diseases like sickle cell disease. Kamau Therapeutics will gain non-exclusive rights to MaxCyte’s technologies, enhancing their gene correction capabilities and clinical manufacturing processes. This partnership is expected to accelerate the clinical progression of Kamau’s lead product candidate, nula-cel, which is a potential cure for SCD.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
